Page 52 of 857: studies 511 to 520 of 8,563, newest first. Back to the addiction overview
The American Journal of Drug and Alcohol Abuse January 2, 2018 Deborah C. Mash 29 citations
Ibogaine is an indole alkaloid that comes from the root of the West African shrub Tabernanthe iboga. Ibogaine has been used for centuries in spiritual celebrations, coming of age rituals, and heali...
Substance Abuse and Rehabilitation 2018 Sarah E. Priddy, Matthew O Howard, Adam W. Hanley et al.
Substance use disorders (SUDs) are a pervasive public health problem with deleterious consequences for individuals, families, and society. Furthermore, SUD intervention is complicated by the continuous possibility of relapse. Despite decades of research, SUD relapse rates remain high, underscoring the need for more effective treatments. Scientific findings indicate that SUDs are driven by...
Frontiers in Psychiatry 2018 Jennifer L Jones, Camilo F Mateus, Robert J Malcolm et al.
Background: Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective...
The American Journal of Drug and Alcohol Abuse 2018 Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski 150 citations
The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid dependence. This...
The American Journal of Drug and Alcohol Abuse 2018 Thomas Kingsley Brown, Kenneth Alper 156 citations
Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. To study outcomes following opioid detoxification with ibogaine. In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5...
Frontiers in Pharmacology 2018 Deborah C. Mash, Linda Duque, Bryan Page et al. 109 citations
Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms after only a single dose administration. Preclinical studies in animal models of addiction have provided proof-of-concept evidence in support of these claims....
Progress in Brain Research 2018 Joseph P Barsuglia, Martin Polanco, Robert Palmer et al. 37 citations
Ibogaine is a plant-derived alkaloid and dissociative psychedelic that demonstrates anti-addictive properties with several substances of abuse, including alcohol. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring psychedelic known to occasion potent mystical-type experiences and also demonstrates anti-addictive properties. The potential therapeutic effects of both compounds...
Brazilian Journal of Psychiatry December 16, 2017 Ilana Berlowitz, Christian Ghasarian, Heinrich Walt et al. 39 citations
OBJECTIVE: The harmful use of psychoactive substances represents one of today's largest public health problems. Yet, in spite of its global relevance, current treatment for substance use disorders (SUDs) is still not entirely successful. The purpose of this study was to investigate alternative treatments and conceptions from traditional Amazonian medicine adapted to SUDs. METHODS: We conducted...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging November 23, 2017 Peter Manza, Dardo G. Tomasi, Nora D. Volkow 61 citations
BACKGROUND: Cannabis abuse (CA) has been associated with psychopathology, including negative emotionality and higher risk of psychosis, particularly with early age of initiation. However, the mechanisms underlying this association are poorly understood. Because aberrant dopamine signaling is implicated in cannabis-associated psychopathology, we hypothesized that regular CA would be associated...
Journal of Consulting and Clinical Psychology November 1, 2017 Corey Roos, Sarah Bowen, Katie Witkiewitz
Objective: Few studies have evaluated moderators of mindfulness-based relapse prevention (MBRP) for substance use disorders (SUDs). We tested whether baseline patterns of scores for SUD symptom severity and depression and anxiety symptoms moderated the efficacy of MBRP. Method: We used a latent class moderation approach with data from a randomized trial of MBRP compared to cognitive–behavioral...